Meet the Experts Transporter Webinar - Breast Cancer Resistance Protein (BCRP)-Mediated Drug-Drug Interactions: Clinical Implications and Quantitative Risk Assessment
Welcome
Like much of the world, we are limiting our travel and putting face-to-face meetings on hold as a result of the COVID-19 pandemic. The pace of scientific progress continues however, and with it the need for discourse and debate. Since taking the difficult decision to postpone our Meet the Experts Transporter Conference at the start of the year, we have received a significant level of interest from our colleagues in the transporter field for an alternative venue in which to showcase the latest in transporter research. We are therefore delighted to announce the start of the SOLVO Biotechnology Meet the Experts Transporter Webinar Series!
Speakers
VARMA, Manthena, PhD
Research Fellow, Pfizer Inc. Groton, CT, USA
Biography
Manthena Varma, PhD is Research Fellow, at Pfizer Inc. Dr. Varma received his B. Pharm. degree from the Kakatiya University, Warangal, India; and an M.S. degree (2001) and PhD in Pharmaceutics (2005), from the National Institute of Pharmaceutical Education and research (NIPER), Mohali, India. Later, Dr. Varma worked as a Post Doctoral Fellow at the Department of Pharmaceutics, University of Minnesota (Minneapolis). In 2008, he joined Worldwide R&D, Pfizer, Groton, CT. Dr. Varma holds an Adjunct faculty position in the Department of Pharmacy of the University of Rhode Island. Dr. Varma’s research is focused in the fields of ADME/PK technologies and strategies in drug design and development, role of drug transporters and transporter-enzyme interplay (extended clearance) in ADME/PK, clinical pharmacokinetics and DDI predictions/evaluation via mechanistic (PBPK) modeling. He published about 125 original articles/reviews and presented over 75 presentations at the scientific conferences in these areas.
Timing
Date: October 6, 2021
8:00 am (PT)
11:00 am (ET)
4:00 pm (GMT)
5:00 pm (CET)
6:00 pm (IST)
12:00 pm (Beijing)
01:00 am (Tokyo, Seoul)
Abstract
Breast Cancer Resistance Protein (BCRP)-Mediated Drug-Drug Interactions: Clinical Implications and Quantitative Risk Assessment
Breast cancer resistance protein (BCRP; ABCG2) is an ATP-binding cassette efflux transporter expressed in the apical membrane of the small intestine and liver canalicular membrane and plays a key role in the oral absorption and hepatic elimination of substrate drugs. Furthermore, BCRP was suggested to be an important loci of drug-drug interactions (DDIs) in humans. Regulatory guidance from agencies including European Medical Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA, Japan), and United States Food and Drug Administration (USFDA) now recommend appropriate in vitro and/or in vivo assessment of investigational drugs for potential to inhibit several drug transporters including BCRP. Quantitative assessment of DDIs involving BCRP inhibition is challenged by overlapping substrate/inhibitor specificity. This presentation summarizes our recent work assessing in vitro data-informed static model predictions and PBPK modeling to delineate the effects of inhibitor drugs on BCRP- and organic anion transporting polypeptide (OATP)1B-mediated disposition of rosuvastatin, which is a recommended BCRP clinical probe. Leveraging the collective learnings from the static analysis and PBPK modeling and simulations, a strategy to enable BCRP DDI risk assessment will be discussed with case examples.
